Shanghai, China & Incheon, South Korea – Phrontline Biopharma, a clinical-stage biotechnology company dedicated to developing a new generation of Antibody-Drug Conjugates (ADCs), today announced it has entered a global strategic collaboration with Samsung Bioepis Co., Ltd. to jointly develop best-in-class ADC therapies for the treatment of solid tumors.

Collaboration Highlights:

• Co-Development:The two parties will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers.

• Pipeline Expansion:The collaboration will add a novel class of **bispecific, dual-payload ADC therapies to Samsung Bioepis' oncology portfolio.

• Technology Leadership:Phrontline will lead in creating novel ADCs leveraging its proprietary bispecific antibody and Dual-Linker Payload (DLP) platforms.

• Technology Licensing:Samsung Bioepis receives an exclusive license from Phrontline for one TOP1i payload for the development, manufacturing, and commercialization of its ADC pipeline.

• Financial Terms:Under the agreement, Phrontline will receive an upfront payment and is eligible to receive additional payments tied to development and regulatory milestones.

Executive Perspectives

“Phrontline's innovative bispecific targeting technology and Dual-Linker Payload platform enable the efficient simultaneous delivery of two therapeutic payloads with distinct mechanisms of action,” said Tony Chen, Founder and Chief Executive Officer of Phrontline Biopharma. “This collaboration accelerates our vision of establishing bispecific, dual-payload ADCs as next-generation precision oncology medicines. Working with Samsung Bioepis, we will start with TJ108 to collectively address the challenges of drug resistance, tumor heterogeneity, and durability of response that limit current single-target, single-payload ADCs.”

“We are pleased to partner with Phrontline to co-develop differentiated ADC drugs targeting a broad range of indications,”said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. “We will continue to explore new business opportunities by leveraging our proven development platforms to address patients' unmet medical needs.”

About Phrontline Biopharma 

Phrontline Biopharma is a clinical-stage biotechnology company headquartered in Suzhou, China. The company's mission is to develop a new class of bispecific, dual-payload antibody-drug conjugates (ADCs) designed to overcome the limitations of existing single-target, single-payload ADCs, particularly in addressing tumor drug resistance, heterogeneity, and improving durability of response. The company has established proprietary bispecific antibody and Dual-Linker Payload (DLP) platforms and is committed to advancing more effective and durable treatment options for patients with high unmet medical needs.

For more information, please visit: [www.phrontlinebio.com]

About Samsung Bioepis 

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to making quality healthcare accessible globally. Through excellence in product development and an unwavering commitment to quality, Samsung Bioepis aims to become a leading global biopharmaceutical company. While continuously expanding its biosimilar pipeline, the company has extended its R&D areas to cover multiple therapeutic fields, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology.

For more information, please visit: [www.samsungbioepis.com]